Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Borderline resectable pancreatic cancer.

Gauri R Varadhachary1, Eric P Tamm, Christopher Crane

  • 1Department of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. gvaradha@mdanderson.org

Current Treatment Options in Gastroenterology
|September 16, 2005
PubMed
Summary

Defining borderline resectable pancreatic cancer is crucial for clinical trials. Neoadjuvant therapy followed by surgery is favored for these high-risk patients to improve outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Modern Presentation, Etiology, and Rate of Occurrence of Cushing Syndrome Differs when Compared to Prior Population-Based Studies.

AACE endocrinology and diabetes·2026
Same author

AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma.

JAMA surgery·2026
Same author

Patient-specific fine-tuning of a self-distilled transformer model for normal tissue segmentation in abdominal magnetic resonance guided adaptive radiotherapy.

Physics and imaging in radiation oncology·2026
Same author

Development and implementation of an innovative mentoring committee for early-career faculty members.

Surgery·2026
Same author

Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report.

Frontiers in oncology·2026
Same author

Adrenalectomy patients with mixed primary aldosteronism and hypercortisolism: An analysis of outcomes following surgery at a single institution.

Surgery·2025

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Accurate definition of borderline resectable pancreatic cancer is essential for clinical trial enrollment.
  • Current criteria include specific degrees of vascular abutment or encasement and venous occlusion.
  • These tumors pose a high risk of positive surgical margins upon initial resection.

Purpose of the Study:

  • To establish rigorous criteria for defining borderline resectable pancreatic cancer.
  • To outline a treatment strategy involving neoadjuvant therapy for these patients.
  • To emphasize the need for well-defined eligibility criteria in prospective clinical trials.

Main Methods:

  • Utilizing specific imaging criteria: superior mesenteric artery abutment (<=180 degrees), common hepatic artery abutment/encasement (>=50%), and segmental venous occlusion.

Related Experiment Videos

  • Implementing a treatment schema favoring preoperative (neoadjuvant) therapy with systemic chemotherapy and chemoradiation.
  • Selecting patients for pancreaticoduodenectomy based on radiographic stability or regression and improved serum tumor markers.

    • Main Results:

    • The proposed criteria aid in categorizing pancreatic tumors as borderline resectable.
    • Neoadjuvant therapy followed by pancreaticoduodenectomy is a favored approach for eligible patients.
    • Vascular resection and reconstruction may be necessary, requiring specialized surgical centers.

    Conclusions:

    • Clear criteria for borderline resectable pancreatic cancer are vital for effective clinical trial design.
    • A neoadjuvant treatment approach followed by surgical resection is recommended for this patient group.
    • Multicenter trials with precise eligibility criteria are needed to determine optimal treatment strategies.